ANNEXIN A3 AUTOIMMUNE REGULATION OF PROSTATE CANCER Russian patent published in 2013 - IPC G01N33/574 

FIELD: medicine.

SUBSTANCE: diagnostic technique for prostate cancer involves detecting the subcellular distribution of annexin A3 in a biological sample, and wherein if the apical intracellular localisation of annexin A3 is detected, a benign growth or pre-cancer is diagnosed, and the diffuse intracellular localisation of annexin A3 enables diagnosing a malignancy. The diagnostic technique for prostate cancer may also involve detecting in a sample the presence and/or the count of anti-annexin A3 autoantibodies, and optionally the presence and/or the count of regulatory T-cells, wherein the presence of the ANXA3 autoantibodies and/or the presence of significant amounts of intracellular ANXA3-positive, other than apical regulatory T-cells testifies to the malignancy. The group of inventions also concerns an analytical reagent for diagnosing prostate cancer, a method of updating the diagnosis in an individual related to an intermediate risk group of prostate cancer.

EFFECT: group of inventions provides the differentiation of the benign growth and malignancy.

16 cl, 1 ex, 5 dwg, 3 tbl